Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients.
Rashid
I
I
Department of Nephrology, New York Medical College, Valhalla, NY, USA.
El-Sabrout
R
R
Butt
F
F
Delaney
V
V
Qadir
M
M
Hanson
P
P
Butt
K
K
D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D007518:Isoantibodies; D020123:Sirolimus; D016559:Tacrolimus